Seung Kak Shin

12PUBLICATIONS
45CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Legal institutions (incl. courts and justice systems)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 09, 2026
Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB.

Seong Hee Kang, Hyung Joon Yim, Seul Ki Han

|Jul 25, 2025
A Real-World Retrospective Cohort Study on the Clinical Effect of Silymarin (Legalon) on Liver Damage and Diseases Using a Domestic Multicenter Common Data Model.

Byoung Kuk Jang, Seung Kak Shin, Jae Yoon Jeong

|Jan 27, 2025
Current Landscape of Adoptive Cell Therapy and Challenge to Develop "Off-The-Shelf" Therapy for Hepatocellular Carcinoma.

Seung Kak Shin, Yuta Mishima, Yoonseok Lee

|Sep 02, 2024
Local Ablation for Hepatocellular Carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.

Seungchul Han, Pil Soo Sung, Soo Young Park

|Aug 28, 2024
Local Ablation for Hepatocellular Carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.

Seungchul Han, Pil Soo Sung, Soo Young Park

|May 27, 2024
Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma.

Seung Kak Shin, Sooyeon Oh, Su-Kyung Chun

Pageof 2

Frequent Collaborators

4 joint publications

Ju Hyun Kim

3 joint publications

Young Kul Jung

3 joint publications

Yun Soo Kim

2 joint publications

Pil Soo Sung